Skip to content

The effect of silymarin on serum liver enzyme level in patients with trauma

Comparison of the effect of silymarin and placebo on serum liver enzyme level in patients with trauma in the Intensive Care Unit in Rajaei hospital

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190911044744N1
Enrollment
90
Registered
2019-09-22
Start date
2019-10-11
Completion date
Unknown
Last updated
2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Trauma. Contusion of liver

Interventions

Intervention 1: Intervention group: Receiving Livergol tablet 140 mg Goldaru factory orally every eight hours for 14 days yo reduce liver enzyme levels. Intervention 2: Control group: Receiving placeb

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to No maximum

Inclusion criteria

Inclusion criteria: People aged 16 or over Not taking a known hepatotoxic drug Not taking oral silymarin during the past day No confirmed history of allergic reactions following oral administration of silymarin Alanine aminotransferase (ALT) levels more than 2-fold above normal (> 70 IU / L) up to 4-fold above normal Or aspartate aminotransferase (AST) levels more than 2-fold above normal (> 70 IU / L) up to 4-fold above normal Not taking concomitant antioxidants or compounds such as vitamin A, C, E and N-acetyl cysteine Oral tolerance to medications

Exclusion criteria

Exclusion criteria: Pregnancy or lactation History of advanced liver disease

Design outcomes

Primary

MeasureTime frame
Decreased liver enzyme levels. Timepoint: Start of study, end of first week, end of second week. Method of measurement: Blood test.;Measurement of free radicals. Timepoint: The beginning and the end of the study. Method of measurement: Blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Mirzaei

Shiraz University of Medical Sciences

ehsan.mirzaei.1369@gmail.com+98 71 3242 4127

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026